PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

ABSTRACT:

Importance

Uveal melanoma (UM) is an intraocular primary malignant neoplasm that often gives rise to metastatic disease for which there are no effective therapies. A substantial proportion of UMs express the cancer-testis antigen PRAME (preferentially expressed antigen in melanoma), which can potentially be targeted by adoptive T-cell therapy.

Objective

To determine whether there may be a rationale for PRAME-directed T-cell therapy for metastatic UM.

Design, setting, and participants

An experimental study using a retrospective cohort of 64 patients with UM (median follow-up, 62 months) was conducted from January 8, 2015, to November 20, 2016, at the Leiden University Medical Center. Clinical, histopathologic, and genetic parameters were compared between 64 PRAME-posit

SUBMITTER: Gezgin G 

PROVIDER: S-EPMC5509351 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature